retatrutide triple agonist glp-1 gip glucagon receptor The future of metabolic science begins here. represents a new generation of metabolic therapies by acting simultaneously on GLP-1, and receptors—a designed to support multiple pathways involved Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon
Pay in 4 interest-free payments of $5.90 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16



























